Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 06:00 ET | Source: Celon Pharma

FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial

FDA clears path for Phase 3 testing following positive Type B meetingRegulatory alignment confirms preclinical data sufficient for pivotal initiationPhase 3 to include two 28-day trials and a 12-month...
March 04, 2025 16:05 ET | Source: Celon Pharma

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease

Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7Favorable...
July 09, 2024 07:53 ET | Source: Celon Pharma

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic

-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) at Week 4- -Dose-response was...
June 17, 2024 16:05 ET | Source: Celon Pharma

Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)

KIELPIN, Poland, June 17, 2024 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid...
June 22, 2021 12:45 ET | Source: Celon Pharma

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2...
April 19, 2021 08:00 ET | Source: Celon Pharma

Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st

KIELPIN, Poland, April 19, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced that it will host a virtual Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET. The...
April 01, 2021 03:30 ET | Source: Celon Pharma

Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial

KIELPIN, Poland, April 01, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL’280. This agent is in...
February 10, 2021 09:00 ET | Source: Celon Pharma

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was...
January 08, 2021 14:16 ET | Source: Celon Pharma

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation)...